TELA
TELA Bio, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$1.23
−5.04%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.31
From 52W high−24.38%
Volume390934.00
Market cap$55.30M
P/E (TTM)—
P/S (TTM)0.7x
Div yield—
Key dataSep 18, 2026
Open
$1.31
From 52W high
−24.38%
Volume
390934.00
Market cap
$55.30M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.5x
P/E (TTM)
—
RSI (14)
74.6
MomentumView details →
1D Return
−5.04%
YTD Return
+3.28%
SummaryUpdated Jun 1, 2026
TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company founded in 2012 and headquartered in Malvern, Pennsylvania. The company went public in November 2019 and specializes in developing and commercializing soft-tissue reconstruction solutions for hernia repair and plastic surgery applications. TELA Bio focuses on providing alternatives to traditional synthetic mesh products by offering reinforced tissue matrices derived from natural ovine (sheep) tissue combined with synthetic materials to optimize patient outcomes while preserving anatomical integrity.
Similar companies
Latest newsMore news →
Heather Getz was appointed principal financial officer of TELA Bio, Inc., effective August 31, 2026.20d agoTELA Bio announced a transition in its Chief Operating Officer and Chief Financial Officer roles.20d agoTELA Bio announced a strategic cost reduction initiative to reduce annual operating expenses by $17.0 million or 18%.20d ago